ARQT — Arcutis Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $3.66bn
- $3.53bn
- $376.07m
Arcutis Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary
Arcutis Biotherapeutics up after Q1 revenue rises
Arcutis Biotherapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Arcutis Appoints Former Morgan Stanley Exec David Topper As CFO
Brief: Arcutis Presents Late-Breaking Data From Integument-Ped Phase 3 Trial Of Roflumilast Cream
U.S. STOCKS ON THE MOVE-Boeing, Chemours, C3.ai
U.S. STOCKS ON THE MOVE-Voyager Therapeutics, GoodRx Holdings, Tenet Healthcare
Arcutis Biotherapeutics drops on $150 mln stock deal
Brief: Arcutis Announces Pricing Of $150 Million Public Offering
Brief: Arcutis Announces Proposed Public Offering
Brief: Arcutis And Sato Announce Strategic Collaboration And Licensing Agreement For Topical Roflumilast In Japan
Arcutis Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Arcutis Biotherapeutics Q4 basic EPS USD -0.72
Arcutis Biotherapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview
Arcutis Biotherapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Intuit, Penumbra
Brief: Arcutis Biotherapeutics Files For Mixed Shelf Of Upto $300 Million - SEC Filing
Brief: Steven Cohen Reports 5.2% Passive Stake In Arcutis Biotherapeutics As Of Jan 30, 2024 - SEC Filing
U.S. STOCKS ON THE MOVE-Macy's, Spirit Airlines, Gilead Sciences